Arkuda emerges from Atlas with genetic dementia program

Atlas-founded Arkuda debuts with genetically-defined frontotemporal dementia therapy, $44M A round

Atlas-founded Arkuda is developing compounds for frontotemporal dementia due to genetic lysosomal deficits that could be applied to other neurodegenerative diseases linked to lysosomal dysfunction.

Arkuda Therapeutics Inc. debuted Thursday with a $44 million series A co-led by Atlas Venture and Pfizer Ventures with participation from Tekla Capital Management, BioInnovation Capital and other, undisclosed investors.

The company was founded in 2018 by President and CEO Gerhard Koenig, an Atlas entrepreneur in residence; SVP,

Read the full 723 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury


Article Purchase

This article may not be distributed to non-subscribers